Bayer (BAYN) PT Set at €69.00 by Nord/LB

Bayer (FRA:BAYN) received a €69.00 ($80.23) price target from stock analysts at Nord/LB in a research report issued on Thursday. The firm currently has a “neutral” rating on the healthcare company’s stock. Nord/LB’s price target would indicate a potential upside of 8.58% from the company’s previous close.

Several other equities analysts have also recently commented on BAYN. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Bayer and gave the company a “buy” rating in a report on Thursday. Goldman Sachs Group set a €78.00 ($90.70) price target on Bayer and gave the company a “buy” rating in a report on Thursday, November 29th. Credit Suisse Group set a €77.00 ($89.53) price target on Bayer and gave the company a “buy” rating in a report on Tuesday, November 27th. Societe Generale set a €72.00 ($83.72) price target on Bayer and gave the company a “neutral” rating in a report on Thursday. Finally, Kepler Capital Markets set a €84.00 ($97.67) price target on Bayer and gave the company a “buy” rating in a report on Thursday. Six research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of €91.25 ($106.10).

Bayer stock opened at €63.55 ($73.90) on Thursday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: Find a Trading Strategy That Works

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply